NASDAQ:KZR
Kezar Life Sciences Inc Stock News
$0.766
-0.0023 (-0.299%)
At Close: May 17, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
05:56pm, Monday, 09'th Oct 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
11:17am, Wednesday, 04'th Oct 2023
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
10:33pm, Sunday, 24'th Sep 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big phar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune med
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 04'th Jan 2023
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated a
Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold
01:23am, Wednesday, 16'th Nov 2022
Following a shift in market sentiment, I've narrowed my rating for Kezar Life Sciences from buy to hold. The market has heavily discounted KZR's growth catalysts of clinical trial updates and regulato
SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
07:00am, Thursday, 01'st Sep 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
01:45pm, Wednesday, 27'th Jul 2022
Recent clinical trial momentum has started to inflect positive on the chart for Kezar Life Sciences. The stock has caught a bid in June whilst reducing equity beta to the broad sector, illustrating th
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
04:30pm, Thursday, 07'th Jul 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Biotech ETF Tops in June: 5 Stocks That Outperform
02:52pm, Thursday, 30'th Jun 2022
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bar
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet
11:44am, Thursday, 30'th Jun 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 135.4% in Kezar Life Sciences, Inc. (KZR). While the effectiveness of this highly sought-after metric is questi
Wells Fargo Beefs Up Kezar Life Price Target - Read Why
04:10pm, Tuesday, 28'th Jun 2022
Wells Fargo reiterated its Overweight rating and raised its price target to $17 from $13 for Kezar Life Sciences Inc (NASDAQ: KZR) on zetomipzomib's (zeto) positive Ph2 MISSION data in lupus ne
